Telomerase-specific virotherapy for human squamous cell carcinoma

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. They are designed to induce lysis after propagation within the tumor. Human telomerase is active in over 85% of primary cancers and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Objectives: Oncolytic viruses, Telomelysin and TelomeScan, that combine the specificity of hTERT promoter-based expression systems with the lytic efficacy of replicative viruses were developed. The goal was to confirm the efficacy of the viruses for human squamous cell carcinoma. Results/conclusion: Squamous cell carcinoma of the head and neck (SCCHN) is characterized by locoregional spread, and is clinically accessible, making it an attractive target for intratumoral virotherapy. The viruses replicated efficiently and induced killing in a panel of human cancer cell lines including SCCHN cells in vitro and in vivo . These results illustrate the potential of telomerase-specific oncolytic viruses for treatment of human SCCHN.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Telomerase
Viruses
Squamous Cell Carcinoma
Oncolytic Viruses
Neoplasms
Oncogenic Viruses
Tumors
Cell Line
Epithelial Cells
Cells
Carcinoma, squamous cell of head and neck
human TERT protein

Keywords

  • Adenovirus
  • GFP
  • hTERT
  • Imaging
  • SCCHN
  • Telomerase

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Telomerase-specific virotherapy for human squamous cell carcinoma. / Fujiwara, Toshiyoshi.

In: Expert Opinion on Biological Therapy, Vol. 9, No. 3, 03.2009, p. 321-329.

Research output: Contribution to journalArticle

@article{6e826434adb14af4a7cbe15b71f32a30,
title = "Telomerase-specific virotherapy for human squamous cell carcinoma",
abstract = "Background: Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. They are designed to induce lysis after propagation within the tumor. Human telomerase is active in over 85{\%} of primary cancers and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Objectives: Oncolytic viruses, Telomelysin and TelomeScan, that combine the specificity of hTERT promoter-based expression systems with the lytic efficacy of replicative viruses were developed. The goal was to confirm the efficacy of the viruses for human squamous cell carcinoma. Results/conclusion: Squamous cell carcinoma of the head and neck (SCCHN) is characterized by locoregional spread, and is clinically accessible, making it an attractive target for intratumoral virotherapy. The viruses replicated efficiently and induced killing in a panel of human cancer cell lines including SCCHN cells in vitro and in vivo . These results illustrate the potential of telomerase-specific oncolytic viruses for treatment of human SCCHN.",
keywords = "Adenovirus, GFP, hTERT, Imaging, SCCHN, Telomerase",
author = "Toshiyoshi Fujiwara",
year = "2009",
month = "3",
doi = "10.1517/14712590802715731",
language = "English",
volume = "9",
pages = "321--329",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Telomerase-specific virotherapy for human squamous cell carcinoma

AU - Fujiwara, Toshiyoshi

PY - 2009/3

Y1 - 2009/3

N2 - Background: Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. They are designed to induce lysis after propagation within the tumor. Human telomerase is active in over 85% of primary cancers and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Objectives: Oncolytic viruses, Telomelysin and TelomeScan, that combine the specificity of hTERT promoter-based expression systems with the lytic efficacy of replicative viruses were developed. The goal was to confirm the efficacy of the viruses for human squamous cell carcinoma. Results/conclusion: Squamous cell carcinoma of the head and neck (SCCHN) is characterized by locoregional spread, and is clinically accessible, making it an attractive target for intratumoral virotherapy. The viruses replicated efficiently and induced killing in a panel of human cancer cell lines including SCCHN cells in vitro and in vivo . These results illustrate the potential of telomerase-specific oncolytic viruses for treatment of human SCCHN.

AB - Background: Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. They are designed to induce lysis after propagation within the tumor. Human telomerase is active in over 85% of primary cancers and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Objectives: Oncolytic viruses, Telomelysin and TelomeScan, that combine the specificity of hTERT promoter-based expression systems with the lytic efficacy of replicative viruses were developed. The goal was to confirm the efficacy of the viruses for human squamous cell carcinoma. Results/conclusion: Squamous cell carcinoma of the head and neck (SCCHN) is characterized by locoregional spread, and is clinically accessible, making it an attractive target for intratumoral virotherapy. The viruses replicated efficiently and induced killing in a panel of human cancer cell lines including SCCHN cells in vitro and in vivo . These results illustrate the potential of telomerase-specific oncolytic viruses for treatment of human SCCHN.

KW - Adenovirus

KW - GFP

KW - hTERT

KW - Imaging

KW - SCCHN

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=65549095995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549095995&partnerID=8YFLogxK

U2 - 10.1517/14712590802715731

DO - 10.1517/14712590802715731

M3 - Article

C2 - 19216621

AN - SCOPUS:65549095995

VL - 9

SP - 321

EP - 329

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 3

ER -